Nano-Omics: Nanotechnology-Enabled Multi-Omics Analysis of the Blood-Circulating Cancerome
This Nature Reviews Clinical Oncology paper introduces the nano-omics paradigm, combining nanotechnology tools with multi-omics liquid biopsy approaches for cancer screening, diagnosis, and monitoring. The authors review advances in genomic, epigenomic, transcriptomic, proteomic, and metabolomic analysis of blood-borne tumour derivatives. They argue that integrating nanotechnology-based enrichment with multi-dimensional omics data can uncover novel biomarkers and improve assay sensitivity and specificity for early-stage cancer detection.
The original study
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome.
- Authors
- Gardner L, Kostarelos K, Mallick P, Dive C, Hadjidemetriou M
- Journal
- Nature reviews. Clinical oncology
- Type
- Journal Article, Review, Research Support, Non-U.S. Gov't
- PMID
- 35739399
Original abstract
Over the past decade, the development of 'simple' blood tests that enable cancer screening, diagnosis or monitoring and facilitate the design of personalized therapies without the need for invasive tumour biopsy sampling has been a core ambition in cancer research. Data emerging from ongoing biomarker development efforts indicate that multiple markers, used individually or as part of a multimodal panel, are required to enhance the sensitivity and specificity of assays for early stage cancer detection. The discovery of cancer-associated molecular alterations that are reflected in blood at multiple dimensions (genome, epigenome, transcriptome, proteome and metabolome) and integration of the resultant multi-omics data have the potential to uncover novel biomarkers as well as to further elucidate the underlying molecular pathways. Herein, we review key advances in multi-omics liquid biopsy approaches and introduce the 'nano-omics' paradigm: the development and utilization of nanotechnology tools for the enrichment and subsequent omics analysis of the blood-circulating cancerome.